Loading data for FBIO — first visit, this takes a few seconds.

Alert

Fortress Biotech Inc. (FBIO)

NasdaqCM: FBIO · Real-Time Price · USD

2.80

-0.01 (-0.36%)

At close: Aug 27, 2026, 8:00 PM

2.83

+1.03%

After-hours: 6:09 PM

The price, the headline numbers and the latest news, in one place.

-0.36% (1D)

No data available

Bid	2.03
Market Cap	93.38M
Revenue (ttm)	68.47M
Net Income (ttm)	103.37M
	1.21
	2.77
	1.01
	-1.59
P/B (ttm)	0.57
P/S (ttm)	1.36
Earnings Date	Aug 13, 2025

Ask	3.58
Volume	460,317
Avg. Volume (20D)	608,074
Open	2.84
Previous Close	2.81
Day's Range	2.78 - 2.88
52-Week Range	2.18 - 4.53
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About FBIO

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 17, 2011

Employees 78

Stock Exchange NasdaqCM

Ticker Symbol FBIO

Website https://www.fortressbiotech.com

Full Company Profile

Financial Performance

In 2025, Fortress Biotech's revenue was 63.26M, an increase of 9.69% compared to the previous year's 57.67M. Earnings were 6.82M, a decrease of -114.82%.

Financial Statements

Earnings Surprise

Fortress Biotech has released their quarterly earnings on Aug 13, 2026:

Revenue of $16.04M misses estimates by $0, with 22.06% YoY growth.
EPS of -0.08 exceeds estimates by 0.12, with 84.31% YoY growth.

Next Earnings Release

Fortress Biotech Inc. is scheduled to release its earnings on Aug 13, 2025, after market closes.
Analysts project revenue of ... Upgrade

News

1 week ago · Moby

Fortress Biotech, Inc. Q2 2026 Earnings Call Summary

Moby summary of Fortress Biotech, Inc.'s Q2 2026 earnings call

1 week ago · Motley Fool

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Emrosi prescriptions jumped 20% sequentially with payer coverage climbing to 38%.

2 weeks ago · MarketBeat

Fortress Biotech Q2 Earnings Call Highlights

Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Exe...

2 months ago · Simply Wall St.

Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes

Journey Medical is back in focus as analysts revisit their price targets in light of fresh information around its role inside Fortress Biotech and the implied value of its shares and cash position. Re...

6 months ago · TipRanks

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Re...

Page 1 of 2

Fortress Biotech Inc. (FBIO)